Management of SARS-CoV-2 infection is a major challenge in patients with lymphoid malignancies: Warrants a clear therapeutic strategy

doi:10.5501/wjv.v11.i4.204

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 4

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3982)

All Articles published online

The chart showing PDF series, WORD series, HTML series.

Item

Count

PDF

239

WORD

HTML

1916

Sum=2217

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

573

Download

1191

Sum=1764

Jul 25, 2022 (publication date) through Mar 11, 2026

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Virology

ISSN

2220-3249

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Letter to the Editor

World J Virol. Jul 25, 2022; 11(4): 204-207
Published online Jul 25, 2022. doi: 10.5501/wjv.v11.i4.204

Management of SARS-CoV-2 infection is a major challenge in patients with lymphoid malignancies: Warrants a clear therapeutic strategy

Tarun Sahu, Henu Kumar Verma, Bhaskar Lvks

Tarun Sahu, Physiology, All India Institute of Medical Science, Raipur 492001, Chhattisgarh, India

Henu Kumar Verma, Department of Immunopathology, Institute of Lung Health and Immunity, Comprehensive Pneumology Center, Helmholtz Zentrum, Munich 80331, Bayren, Germany

Bhaskar Lvks, Zoology, Guru Ghasidas Vishwavidyalaya, Bilaspur 495001, Chhattisgarh, India

Author contributions: Sahu T, Verma HK, Lvks B wrote and revised the letter.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Corresponding author: Henu Kumar Verma, PhD, Research Scientist, Department of Immunopathology, Institute of Lung Health and Immunity, Comprehensive Pneumology Center, Helmholtz Zentrum, Ingolstädter Landstrasse 1, Munich 80331, Bayren, Germany, henu.verma@yahoo.com

Received: June 5, 2021
Peer-review started: June 5, 2021
First decision: July 27, 2021
Revised: July 28, 2021
Accepted: May 27, 2022
Article in press: May 27, 2022
Published online: July 25, 2022
Processing time: 411 Days and 10.8 Hours

Abstract

Patients with lymphoid malignancies are at a higher risk of coronavirus disease 2019 (COVID-19) infection due to their immunocompromised state and results in higher mortality rates in these patients. Anti-CD 20 therapy is one of the leading causes of immunosuppression that worsens in COVID-19 cases. COVID-19 vaccines, on the other hand, appear to be less beneficial to these patients. App-ropriate treatment and recommendations are required for these COVID-19 patients with lymphoid malignancies.

Keywords: COVID-19; Lymphoid malignancy; Lymphoma; Vaccination; Immuno-suppression

Core Tip: Patients with hematologic conditions are two times more likely than others to be admitted to the hospital. They are being treated with anti-cancer drugs, which weakens their immune system. As a result, these patients are always at risk of coronavirus disease 2019 (COVID-19). As we know, the COVID-19 is very lethal, and hematological malignancies are likely to increase the risk of negative outcomes from this viral infection. Currently, there are no guidelines for treating COVID-19 infected patients with hematological malignancies.